FDA panel unanimously backs Moderna booster jabs for high-risk people
Committee will weigh whether to make a similar recommendation for Johnson & Johnson’s vaccine on Friday
14 October 2021 - 21:53
byManas Mishra and Julie Steenhuysen
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
A healthcare worker holds a vial of the Moderna vaccine at a vaccination site in New York, the US, January 29 2021. Picture: REUTERS/MIKE SEGAR
A panel of expert advisers to the US Food and Drug Administration (FDA) unanimously voted on Thursday to recommend booster shots of Moderna’s Covid-19 vaccine for Americans aged 65 and older and those at high risk of severe illness.
If the FDA signs off on Moderna’s booster, the US Centers for Disease Control and Prevention will make specific recommendations on who should get the shots. CDC advisers are scheduled to meet next week.
The FDA’s vaccines and related biological products advisory committee met on Thursday to consider the additional dose of the Moderna vaccine and will weigh whether to make a similar recommendation for Johnson & Johnson’s vaccine on Friday. The vote to back Moderna’s booster was 19-0.
Moderna is seeking authorisation of a booster that contains 50 micrograms of vaccine, half of strength of its regular dose but still higher than the Pfizer/BioNTech shot at 30 micrograms.
In addition to 65 and over and those at risk of severe Covid-19, the expert panel voted to recommend authorisation of a third round of the Moderna vaccine for individuals ages 18 to 64 at risk of frequent exposure to coronavirus infections due to their jobs. The shots would be administered to people at least six months after the initial two-shot inoculation.
US health officials have been under pressure to authorise Covid-19 vaccine booster doses after the White House announced in August it planned a widespread booster campaign pending approvals from the FDA and the CDC.
Both agencies signed off on Pfizer/BioNTech boosters for certain high-risk adults last month. Since then, nearly 9-million people have received a third shot, the CDC reported on Wednesday.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
FDA panel unanimously backs Moderna booster jabs for high-risk people
Committee will weigh whether to make a similar recommendation for Johnson & Johnson’s vaccine on Friday
A panel of expert advisers to the US Food and Drug Administration (FDA) unanimously voted on Thursday to recommend booster shots of Moderna’s Covid-19 vaccine for Americans aged 65 and older and those at high risk of severe illness.
If the FDA signs off on Moderna’s booster, the US Centers for Disease Control and Prevention will make specific recommendations on who should get the shots. CDC advisers are scheduled to meet next week.
The FDA’s vaccines and related biological products advisory committee met on Thursday to consider the additional dose of the Moderna vaccine and will weigh whether to make a similar recommendation for Johnson & Johnson’s vaccine on Friday. The vote to back Moderna’s booster was 19-0.
Moderna is seeking authorisation of a booster that contains 50 micrograms of vaccine, half of strength of its regular dose but still higher than the Pfizer/BioNTech shot at 30 micrograms.
In addition to 65 and over and those at risk of severe Covid-19, the expert panel voted to recommend authorisation of a third round of the Moderna vaccine for individuals ages 18 to 64 at risk of frequent exposure to coronavirus infections due to their jobs. The shots would be administered to people at least six months after the initial two-shot inoculation.
US health officials have been under pressure to authorise Covid-19 vaccine booster doses after the White House announced in August it planned a widespread booster campaign pending approvals from the FDA and the CDC.
Both agencies signed off on Pfizer/BioNTech boosters for certain high-risk adults last month. Since then, nearly 9-million people have received a third shot, the CDC reported on Wednesday.
Reuters
Moderna considers SA for site of new vaccine factory
CureVac pulls Covid-19 vaccine candidate to focus on work with GSK
Russia to seek approval for Sputnik Light in SA
Patrick Soon-Shiong: SA’s billion-dollar genius
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
AstraZeneca says antibody shot cuts risk of severe Covid by 50%
Covid-19 jabs protect Cape older adults
Developers running final tests on SA’s digital vaccination certificate system
France shares its experience on Covid- 19 vaccine mandate with SA
Sanofi to pull the plug on mRNA Covid-19 vaccine after rivals’ success
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.